Dabrafenib
CAS 1195765-45-7 5 FDA-DMF suppliersSmall Molecule
Overview
Dabrafenib is a medication used in the treatment of certain types of cancer, specifically BRAF V600E mutation-positive unresectable or metastatic melanoma. It works by inhibiting the activity of BRAF, a kinase that is mutated in some cancer cells.
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Dabrafenib expires 29 Dec 2038 and exclusivity 15 Sept 2030. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
OncologyMelanoma
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.